Board Change • May 20
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent Non-Executive Chairman Iain George Ferguson was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Annuncio • Jan 08
Genus plc to Report Fiscal Year 2026 Results on Sep 10, 2026 Genus plc announced that they will report fiscal year 2026 results on Sep 10, 2026 Annuncio • Nov 20
Genus plc Announces Board Appointments Genus plc announced the appointment of Dr Celia Baxter to the Board as a Non-Executive Director with effect from 19 November 2025, and the appointment of Dr Robert Reiter as a Non-Executive Director with effect from 1 January 2026. Dr Baxter has had extensive experience inpeople-driven, multisite, manufacturing, services and distribution businesses across business sectors in international FTSE 100 and FTSE 250 companies as well as Big Four consulting, having worked in increasingly senior Human Resources roles at Ford Motor Company, KPMG, Sherwood Computer Services, Tate & Lyle, Enterprise Oil plc, Hays and Bunzl where she was Group Human Resources Director. Dr Baxter has a PhD in Botany from Reading Universityandis currently a non-executive director and remuneration committee chair of Volution Group plc, senior independent director and remuneration committee chair of discoverIE Group plc, and senior independent director and remuneration committee chair of Dowlais Group plc. She was previously a non-executive director of Senior plc, RHI Magnesita NV and Bekaert SA. Dr Baxter brings widespread global experience in Human Resources, Strategy, Branding, Mergers and Acquisitions and Change Management. Dr Reiteris a plant geneticist by training and spent his executive career delivering innovative new technologies and products within crop agriculture, having worked in E.I. DuPont de Nemours, followed by twenty years in increasingly senior scientific and supply chain leadership roles at Monsanto. Bob was the R&D Integration Planning Lead for the Bayer-Monsanto merger, collaborating with Bayer to design a world-class agricultural R&D organisation, overseeing an annual investment portfolio exceeding $2.3 billion. Following the acquisition of Monsanto, Bob became an Executive Vice President leading Research & Development for the combined Bayer Crop Science division, and integrated the two divisions with accountability of over 7,000 employees. Annuncio • Nov 19
Genus plc to Report First Half, 2026 Results on Feb 26, 2026 Genus plc announced that they will report first half, 2026 results on Feb 26, 2026 Annuncio • Oct 10
Genus plc, Annual General Meeting, Nov 19, 2025 Genus plc, Annual General Meeting, Nov 19, 2025. Location: buchanan communications, 107 cheapside, ec2v 6dn, london United Kingdom Annuncio • Sep 04
Genus plc Proposes Final Dividend for the Year 2025, Payable on December 5, 2025 Genus plc proposed a final dividend of 21.7 pence per share for 2025. This is subject to shareholders' approval at the AGM and we have therefore not included it as a liability in these Financial Statements. The total proposed and paid dividend for year ended 30 June 2025 is 32.0 pence per share (2024: 32.0 pence per share). It is proposed that the final dividend will be paid on 5 December 2025 to the shareholders on the register at the close of business on 7 November 2025. Annuncio • May 02
Genus plc Announces the Update in Relation to Its Innovative Prrs 1 Resistant Pig Programme Genus announced that the U.S. Food and Drug Administration ("FDA") has approved the PRP gene edit for use in the U.S. food supply chain, in line with expectations. This landmark approval follows years of close collaboration with the FDA and is a significant step on the pathway to PRP commercialisation in the U.S. Genus believes successful U.S. commercialisation also requires approvals in key U.S. export markets, being Mexico, Canada and Japan. The Group continues to make progress with regulators in these jurisdictions as well as with other international regulators, including China. Brazil, Colombia and, more recently, the Dominican Republic have already issued positive determinations for PRP, meaning those countries will regulate the PRP the same as any other pigs. PRRS is one of the most devastating global pig diseases and causes suffering and premature death for pigs. Recent research indicates that PRRS also increases the need for antibiotics by more than 200%. Annuncio • Feb 26
Genus plc Announces Retirement of Jason Chin as Non-Executive Director from the Board, Effective from the End of May 2025 Genus plc announced that Professor Jason Chinhas informed the Company of his intention to step down from the Genus Board, effective from the end of May 2025, as he will be taking on a significant new role as Founding Director of the Generative Biology Institute at the Ellison Institute of Technology. Professor Chin has served as a Non-Executive Director, Chairman of the Company's Scientific Advisory Board and advisor to the Company's Global Portfolio Steering Committee for four years. Upon stepping down from the Board, Professor Chin will remain a member of the Scientific Advisory Board. The Board has initiated a comprehensive search for Professor Chin's successor and will provide an update once this process has concluded. Annuncio • Nov 30
Genus plc to Report Fiscal Year 2025 Results on Sep 04, 2025 Genus plc announced that they will report fiscal year 2025 results on Sep 04, 2025 Annuncio • Nov 21
Genus plc Declares A Final Dividend Genus plc declared a final dividend of 21.7 pence per Ordinary Share, at its AGM held on 20 November 2024. Annuncio • Nov 20
Genus plc to Report First Half, 2025 Results on Feb 27, 2025 Genus plc announced that they will report first half, 2025 results on Feb 27, 2025 Annuncio • Oct 22
Genus plc Announces Retirement of Alison Henriksen as Chief Financial Officer, Until 31 July 2025 Genus announced that Alison Henriksen, Chief Financial Officer, has informed the Board of her intention to retire after five years with the Group. Alison will remain in her existing role until 31 July 2025 to assist with the transition and continue to focus on delivery of the Group's strategic priorities until her retirement. Annuncio • Sep 05
Genus plc Proposes Final Dividend for the Year Ended June 30, 2024, Payable on 6 December 2024 Genus plc board proposed a final dividend of 21.7 pence per ordinary share, consistent with the prior year final dividend. Payable on, 6 December 2024 to the shareholders on the register at the close of business on 8 November 2024. Valuation Update With 7 Day Price Move • Mar 04
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to UK£16.49, the stock trades at a forward P/E ratio of 33x. Average trailing P/E is 35x in the Biotechs industry in Europe. Total loss to shareholders of 66% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at UK£18.51 per share. Declared Dividend • Feb 25
First half dividend of UK£0.10 announced Dividend of UK£0.10 is the same as last year. Ex-date: 29th February 2024 Payment date: 28th March 2024 Dividend yield will be 1.6%, which is lower than the industry average of 2.8%. Sustainability & Growth Dividend is covered by earnings (63% earnings payout ratio) but not covered by cash flows (210% cash payout ratio). The dividend has increased by an average of 7.1% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. EPS is expected to grow by 115% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Feb 24
First half 2024 earnings released: EPS: UK£0.21 (vs UK£0.20 in 1H 2023) First half 2024 results: EPS: UK£0.21 (up from UK£0.20 in 1H 2023). Revenue: UK£333.6m (down 4.7% from 1H 2023). Net income: UK£13.5m (flat on 1H 2023). Profit margin: 4.0% (up from 3.8% in 1H 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 27% per year, which means it is performing significantly worse than earnings. Valuation Update With 7 Day Price Move • Feb 16
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to UK£17.83, the stock trades at a forward P/E ratio of 30x. Average trailing P/E is 35x in the Biotechs industry in Europe. Total loss to shareholders of 66% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at UK£17.74 per share. Annuncio • Feb 16
Genus plc Provides Earnings Guidance for the First Half of Fiscal 2024 Genus plc provided earnings guidance for the first half of fiscal 2024. For the first half period, management expects to report revenue of £334 Million. Annuncio • Dec 12
Genus Appoints Ralph Heuser as Non-Executive Director, with effect from 1 January 2024 Genus announced the appointment of Dr Ralph Heuser to the Board as a Non-Executive Director, with effect from 1 January 2024. Dr Heuser has had extensive experience in animal healthcare businesses globally, having worked at Pfizer, Boehringer Ingelheim, where he launched a PRRS vaccine in Germany, Novartis's Consumer and Animal Health divisions and more recentlyin global leadership roles at Elanco Animal Health, including as Vice President for Asia Pacific, Europe and International Commercial Operations. Dr Heuserhas a PhD in Agricultural Economics from the University of Bonn, Germany andis currently a Senior Advisor with Stonehaven Consulting (SC Group) AG. Dr Heuser brings widespread global experience in operations, commercial excellence, integration and the animal health industry generally, and his appointment follows an extensive search process using an external search agency. Annuncio • Nov 23
Genus plc Approves to Declare Final Dividend Genus plc at its AGM held on 22 November 2023, approved to declare a final dividend of 21.7 pence per Ordinary Share. Upcoming Dividend • Nov 02
Upcoming dividend of UK£0.22 per share at 1.4% yield Eligible shareholders must have bought the stock before 09 November 2023. Payment date: 08 December 2023. Payout ratio is a comfortable 63% but the company is paying out more than the cash it is generating. Trailing yield: 1.4%. Lower than top quartile of British dividend payers (6.7%). Lower than average of industry peers (1.7%). Reported Earnings • Oct 15
Full year 2023 earnings released: EPS: UK£0.51 (vs UK£0.63 in FY 2022) Full year 2023 results: EPS: UK£0.51 (down from UK£0.63 in FY 2022). Revenue: UK£689.7m (up 16% from FY 2022). Net income: UK£33.3m (down 19% from FY 2022). Profit margin: 4.8% (down from 6.9% in FY 2022). Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 19% per year, which means it is performing significantly worse than earnings. Annuncio • Oct 08
Colombian Government Gives Positive Determination for Genus's PRRS Virus-Resistant Pigs Genus plc announced that the government of Colombia has given a favourable regulatory determination for Genus's Porcine Reproductive and Respiratory Syndrome virus ("PRRS") resistant pigs. This enables the future sale of such pigs in Colombia. PRRS is one of the most significant diseases in the pig industry, causing severe respiratory distress, increased secondary infections, pregnancy loss and increased morbidity and mortality. There are currently no effective vaccines or treatments. The creation of a PRRS resistant pig therefore represents a significant step forward in the welfare of pigs by protecting themthem from this devastating virus. It is estimated that PRRS costs the US and EU pig industry approximately $2 billion each year. Genus has used its gene editing platform to develop pigs resistant to PRRS, by deleting a very small portion of the pigs' DNA that encodes a protein that the virus uses to enter and infect the pigs' cells. With this small gene edit, the pig is resistant to PRRS, as the virus is unable to enter the cells and replicate. The Colombian government is the first to issue a determination for Genus's PRRS resistant pigs, enabling the future commercialisation of the pigs. The PRRS resistant pigs will be treated in the same way as any other pigs in Colombia. Further regulatory approvals for the PRRS resistant pig are also being sought in the United States, Canada, China, Japan, Mexico, Brazil and other countries. Genus anticipates a decision from the United States Food and Drug Administration in the first half of 2024, to be followed by a phased global launch of the pigs, subject to receiving applicable regulatory approvals. Genus will be hosting a Capital Markets Event in London on 1 November 2023 to provide additional information on its PRRS resistant pig development, registration and commercialisation programme. New Risk • Sep 11
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 34% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. This is currently the only risk that has been identified for the company. Annuncio • Aug 24
Genus plc Announces Lykele Van Der Broek to Step Down from the Genus Board Genus plc announces that Lykele van der Broek, Non-Executive Director, has informed the Company of his intention to step down from the Genus Board, effective from the conclusion of the 2023 Annual General Meeting on 22 November 2023, after nine years' service as a Non-Executive Director. Russell Reynolds has been retained and is in the process of identifying potential successors for Lykele. Annuncio • Aug 11
AB Agri Ltd. completed the acquisition of National Milk Records plc (OFEX:NMRP) from Livestock Improvement Corporation Limited (NZSE:LIC), ICM Investment Management Limited, Genus plc (LSE:GNS), Custodial Capital Management Limited, High Street Partners, Ltd, and Working Capital Partners Ltd. AB Agri Ltd. made an offer to acquire National Milk Records plc (OFEX:NMRP) from Livestock Improvement Corporation Limited (NZSE:LIC), ICM Investment Management Limited, Genus plc (LSE:GNS), Custodial Capital Management Limited, High Street Partners, Ltd, and Working Capital Partners Ltd £45.7 million on June 6, 2023. The offer per share is £2.15. The cash consideration payable to the NMR Shareholders under the terms of the Acquisition will be financed by existing cash resources available to ABF. The Acquisition will be on the terms and subject to the Conditions including, among other things, the approval of Scheme Shareholders at the Court Meeting and the passing of the Resolutions to be proposed at the General Meeting, the CMA confirming in response to a briefing note that it has no further questions or, alternatively, CMA approval, he sanction of the Scheme by the Court; and the Scheme becoming Effective no later than the Long Stop Date. The Acquisition does not require the approval of ABF shareholders. The long stop date of the transaction is February 29, 2024.
Stuart Vincent and Simon Cope-Thompson of N M Rothschild & Sons Limited as financial adviser to ABF, is satisfied that sufficient cash resources are available to ABF to enable it to satisfy in full the cash consideration payable to NMR Shareholders under the terms of the Acquisition. Addleshaw Goddard LLP is providing legal advice to ABF. Gowling WLG (UK) LLP is providing legal advice to NMR. Holly Gillis and Angharad Couch of Citigate Dewe Rogerson Ltd. acted as financial advisor to ABF. Megan Ray and Rachael Brooks of BlytheRay acted as financial advisor to NMR. Adam James and Harry Rees of Canaccord Genuity Limited acted as financial advisor to NMR. Equiniti Limited acted as a transfer agent to NMR. Canaccord Genuity Limited acted as fairness Opinion Provider to NMR. Ashurst LLP acted as legal advisor to N.M. Rothschild & Sons Limited in the transaction.
AB Agri Ltd. completed the acquisition of National Milk Records plc (OFEX:NMRP) from Livestock Improvement Corporation Limited (NZSE:LIC), ICM Investment Management Limited, Genus plc (LSE:GNS), Custodial Capital Management Limited, High Street Partners, Ltd, and Working Capital Partners Ltd on August 9, 2023. Annuncio • Jun 07
AB Agri Ltd. made an offer to acquire National Milk Records plc (OFEX:NMRP) from Livestock Improvement Corporation Limited (NZSE:LIC), ICM Investment Management Limited, Genus plc (LSE:GNS), Custodial Capital Management Limited, High Street Partners, Ltd, and Working Capital Partners Ltd £45.7 million. AB Agri Ltd. made an offer to acquire National Milk Records plc (OFEX:NMRP) from Livestock Improvement Corporation Limited (NZSE:LIC), ICM Investment Management Limited, Genus plc (LSE:GNS), Custodial Capital Management Limited, High Street Partners, Ltd, and Working Capital Partners Ltd £45.7 million on June 6, 2023. The offer per share is £2.15. The cash consideration payable to the NMR Shareholders under the terms of the Acquisition will be financed by existing cash resources available to ABF. The Acquisition will be on the terms and subject to the Conditions including, among other things, the approval of Scheme Shareholders at the Court Meeting and the passing of the Resolutions to be proposed at the General Meeting, the CMA confirming in response to a briefing note that it has no further questions or, alternatively, CMA approval, he sanction of the Scheme by the Court; and the Scheme becoming Effective no later than the Long Stop Date. The Acquisition does not require the approval of ABF shareholders. The long stop date of the transaction is February 29, 2024.
Stuart Vincent and Simon Cope-Thompson of N M Rothschild & Sons Limited as financial adviser to ABF, is satisfied that sufficient cash resources are available to ABF to enable it to satisfy in full the cash consideration payable to NMR Shareholders under the terms of the Acquisition. Addleshaw Goddard LLP is providing legal advice to ABF. Gowling WLG (UK) LLP is providing legal advice to NMR. Holly Gillis and Angharad Couch of Citigate Dewe Rogerson Ltd. acted as financial advisor to ABF. Megan Ray and Rachael Brooks of BlytheRay acted as financial advisor to NMR. Adam James and Harry Rees of Canaccord Genuity Limited acted as financial advisor to NMR. Equiniti Limited acted as a transfer agent to NMR. Canaccord Genuity Limited acted as fairness Opinion Provider to NMR. Buying Opportunity • May 17
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 8.4%. The fair value is estimated to be UK£31.28, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.9% over the last 3 years, while earnings per share has been flat. Reported Earnings • Feb 25
First half 2023 earnings released: EPS: UK£0.20 (vs UK£0.30 in 1H 2022) First half 2023 results: EPS: UK£0.20 (down from UK£0.30 in 1H 2022). Revenue: UK£350.2m (up 25% from 1H 2022). Net income: UK£13.4m (down 33% from 1H 2022). Profit margin: 3.8% (down from 7.1% in 1H 2022). Revenue is forecast to grow 7.1% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 2% per year whereas the company’s share price has fallen by 3% per year. Reported Earnings • Sep 09
Full year 2022 earnings released: EPS: UK£0.63 (vs UK£0.73 in FY 2021) Full year 2022 results: EPS: UK£0.63 (down from UK£0.73 in FY 2021). Revenue: UK£593.4m (up 3.3% from FY 2021). Net income: UK£40.9m (down 14% from FY 2021). Profit margin: 6.9% (down from 8.2% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Reported Earnings • Feb 27
First half 2022 earnings: EPS in line with analyst expectations despite revenue beat First half 2022 results: EPS: UK£0.30 (down from UK£0.46 in 1H 2021). Revenue: UK£281.2m (down 1.6% from 1H 2021). Net income: UK£19.9m (down 34% from 1H 2021). Profit margin: 7.1% (down from 11% in 1H 2021). Revenue exceeded analyst estimates by 1.0%. Over the next year, revenue is forecast to grow 8.9%, compared to a 17% growth forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 49% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth. Recent Insider Transactions • Nov 25
Independent Non-Executive Chairman recently bought UK£224k worth of stock On the 24th of November, Iain G. Ferguson bought around 5k shares on-market at roughly UK£44.80 per share. This was the largest purchase by an insider in the last 3 months. Iain G. has been a buyer over the last 12 months, purchasing a net total of UK£369k worth in shares. Upcoming Dividend • Nov 11
Upcoming dividend of UK£0.22 per share Eligible shareholders must have bought the stock before 18 November 2021. Payment date: 10 December 2021. Trailing yield: 0.5%. Lower than top quartile of British dividend payers (4.1%). Lower than average of industry peers (1.1%). Reported Earnings • Oct 17
Full year 2021 earnings released: EPS UK£0.73 (vs UK£0.54 in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: UK£574.3m (up 4.2% from FY 2020). Net income: UK£47.3m (up 34% from FY 2020). Profit margin: 8.2% (up from 6.4% in FY 2020). Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 33% per year, which means it is significantly lagging earnings growth. Recent Insider Transactions • Oct 15
Chief Operating Officer recently sold UK£336k worth of stock On the 13th of October, William Christianson sold around 6k shares on-market at roughly UK£54.20 per share. In the last 3 months, there was an even bigger sale from another insider worth UK£1.4m. William has been a seller over the last 12 months, reducing personal holdings by UK£1.7m. Recent Insider Transactions • Sep 15
Insider recently sold UK£1.4m worth of stock On the 13th of September, Dan Hartley sold around 25k shares on-market at roughly UK£56.20 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of UK£4.6m more than they bought in the last 12 months. Reported Earnings • Sep 10
Full year 2021 earnings released: EPS UK£0.73 (vs UK£0.62 in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: UK£574.3m (up 4.2% from FY 2020). Net income: UK£47.3m (up 17% from FY 2020). Profit margin: 8.2% (up from 7.3% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 29% per year, which means it is significantly lagging earnings growth. Executive Departure • Jun 09
Independent Non-Executive Director Ian Charles has left the company On the 31st of May, Ian Charles' tenure as Independent Non-Executive Director ended after 2.9 years in the role. We don't have any record of a personal shareholding under Ian's name. A total of 2 executives have left over the last 12 months. The current median tenure of the management team is 4.13 years. Recent Insider Transactions • Apr 02
Independent Non-Executive Chairman recently bought UK£72k worth of stock On the 31st of March, Iain G. Ferguson bought around 2k shares on-market at roughly UK£47.82 per share. In the last 3 months, they made an even bigger purchase worth UK£73k. Iain G. has been a buyer over the last 12 months, purchasing a net total of UK£144k worth in shares. Recent Insider Transactions • Feb 28
Independent Non-Executive Chairman recently bought UK£73k worth of stock On the 25th of February, Iain G. Ferguson bought around 2k shares on-market at roughly UK£48.51 per share. This was the largest purchase by an insider in the last 3 months. This was Iain G.'s only on-market trade for the last 12 months. Reported Earnings • Feb 28
First half 2021 earnings released: EPS UK£0.48 (vs UK£0.36 in 1H 2020) The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: UK£285.7m (up 5.5% from 1H 2020). Net income: UK£31.5m (up 33% from 1H 2020). Profit margin: 11% (up from 8.8% in 1H 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 32% per year, which means it is well ahead of earnings. Is New 90 Day High Low • Feb 11
New 90-day high: UK£53.95 The company is up 22% from its price of UK£44.40 on 12 November 2020. The British market is up 5.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Biotechs industry, which is up 26% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£23.64 per share. Is New 90 Day High Low • Jan 18
New 90-day high: UK£44.92 The company is up 8.0% from its price of UK£41.74 on 20 October 2020. The British market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£25.58 per share. Recent Insider Transactions • Dec 04
CEO & Executive Director recently sold UK£896k worth of stock On the 2nd of December, Stephen Wilson sold around 22k shares on-market at roughly UK£41.56 per share. This was the largest sale by an insider in the last 3 months. Stephen has been a seller over the last 12 months, reducing personal holdings by UK£903k. 
